Akzo Nobel
This article was originally published in The Gray Sheet
Executive Summary
Dutch conglomerate completes divestiture of the in vitro diagnostics business of its Organon Teknika unit to bioMerieux for about $260 mil. Initially proposed in February, the move will expand bioMerieux' diagnostics revenues to about $1 bil. and allow Organon to focus on its core pharmaceuticals business (1"The Gray Sheet" Feb. 19, 2001, p. 14)
You may also be interested in...
BioMerieux Offer For Organon Teknika Would Create $1 Bil. Diagnostics Unit
BioMerieux-Pierre Fabre's Feb. 15 offer to buy Organon Teknika's diagnostic business would increase the French company's worldwide diagnostic revenues almost 44% to roughly $0.9 bil. annually.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.